Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. The results will be made available to the patient's treating physician and the researchers will track whether or not this information is used in routine health care.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adult Patients | Adults receiving health care at the University of Chicago Medical Center. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of incorporating pharmacogenomic testing into routine medical care | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Find out whether availability of pharmacogenomic information impacts drug decision making in the health care setting | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| To determine whether access to pharmacogenomic information improves satisfaction with care. | 5 years |
Inclusion Criteria:
Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial
Life expectancy of at least 3 years
Must be 18 years or older
Must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment OR be 65 years or older OR be reasonably expected to require the use of a prescription medication within the next 5 years
Patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adults receiving ongoing routine medical care and regularly using at least 1 (but no more than 6) prescription medications at the time of enrollment.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| 1200 Patients Project Study Team | Contact | (773) 834-1759 | cpt1200@uchicago.edu | |
| Cancer Clinical Trials Office | Contact | 1-855-702-8222 | cancerclinicaltrials@bsd.uchicago.edu |
| Name | Affiliation | Role |
|---|---|---|
| Peter H O'Donnell, MD | University of Chicago | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Chicago Medical Center | Recruiting | Chicago | Illinois | 60637 | United States |
Not provided
Not provided
Not provided
Not provided
Whole blood and DNA
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D015212 | Inflammatory Bowel Diseases |
| D001327 | Autoimmune Diseases |
| D001778 | Blood Coagulation Disorders |
| D006526 | Hepatitis C |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
| D007154 | Immune System Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
| D014777 | Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
Not provided
Not provided